Over the last 50 years, one of the great mysteries of cancer treatment is why some patient groups respond incredibly well to treatment, such as chemotherapy, while others barely respond at all. Part of the mystery has to do with the genetic makeup of the tumors themselves, with some tumors being highly susceptible to chemotherapeutic agents, while others are barely affected.
However, with the proliferation of electronic medical records and such technologies as the ability to sequence the human genome being developed over the last few decades, there is great promise for the ability of modern data analysis techniques to yield huge results that have never before been possible.
One of America’s foremost entrepreneurs, Eric Lefkofsky, has co-founded a company, Tempus, which is dedicated to the creation of artificial intelligence applications that can be used by doctors in real-time to greatly enhance their knowledge about given treatment regimes and the likelihood of their patients to respond to them. The Tempus system will use a combination of all available medical records, including the patient’s own genome, in order to provide doctors with the most cutting-edge analyses possible, leading to far more accurate medical decisions taken with regards to the types of treatment patients are given.
Lefkofsky believes that one of the most promising areas of development that will begin to seriously transform the practice of medicine has been the exponential decline in the cost of human genomic sequencing. Lefkofsky points out that in the year 2003, the first time a human genome was sequenced, the cost to do so was over $100 million. Lefkofsky points out that, within the next 10 years, the cost is likely to drop below $100.
Lefkofsky firmly believes that this will open up an entire treasure trove of previously completely untapped data, much of which will prove to be invaluable in the treatment of various types of diseases, particularly cancers. Tempus is now developing applications that will use the human genome itself to give doctors a better picture of their patients’ likely outcomes than has ever been before been possible. Through efforts like these, Lefkofsky is helping to change the face of medicine.
NuoDB happens to be an elastic cloud storage company created in 2008. As the brainchild of Barry S. Morris and Jim Starkey, NuoDB’s flexible SQL database system has enabled businesses to manage their data needs way better than their competitors. To date, institutions like the Alfa Systems, UAE Exchange, and Dassault Systemes brag of improved productivity ever since they chose to partner with NuoDB.
Relying on technology created by Edgar F. Codd, an IBM computer scientist, the SQL cloud database has been the one-way ticket for organizations willing to scale their elasticity, eliminate downtime, and at the same time maintain their acid semantics.
Also, the SQL database system from NuoDB has come in handy for many companies willing to boost productivity levels. By tackling millions of digital instructions every second, NuoDB has helped eliminate backlogs that commonly characterize conventional bodies and institutions.
For the many years that NuoDB has been in existence, it has helped corporations scale down on operational costs since unlike its competitors; the company expands its databases by accommodating more servers. Since 2008, NuoDB has been developing its technology to keep up with client demands. Largely, NuoDB has revolutionized a new age of SQL database management, thanks to technology and innovation.
Cancer research is one of the most demanding and time consuming industries in the world. The job requires for long hours of due diligence and testing. Cancer is no joke and the medications that are being developed to fight this disease, can’t be left up to chance. Dr. Clay Siegall is all too familiar with the process as he has done this very thing time and time again. Siegall is the president and founder of Seattle Genetics, which is one of the top biotech companies on earth. Seattle Genetics focuses on developing and commercializing antibody-based therapies.
These powerful medications are much more efficient when it comes to destroying cancer. Unlike the eras of the past, antibody-based therapies are easier on the body, and it won’t make the patient sick. This is a huge bonus since most cancer medications can make the patient feel even more ill than the illness itself. Siegall’s thorough approach to how the medications are developed and delivered, ensures the patients that they’re receiving the best products to help themselves get better. These types of therapies are known as antibody-drug conjugates, and they’re yielding much better results than previous cancer medications.
Siegall does a good job of informing the public of any breakthroughs and upcoming events through blogging. Of course, he’s a very busy man, but he still seems to find time to announce this valuable information. Some of his latest blogs spoke a wide variety of topics such as politics, sports and science.
Rigorous research is one of the key factors that goes into producing high quality medications and Seattle Genetics is no exception. With so many more already in the company’s pipeline, who knows what the next wave of antibody-drug conjugates will do.